Abstract
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patientswith pancreatic cancer. Although survival rates remain relatively unchanged, newermodalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced andmetastatic disease.
Original language | English (US) |
---|---|
Pages (from-to) | 439-457 |
Number of pages | 19 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 19 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2021 |
ASJC Scopus subject areas
- Oncology